219 related articles for article (PubMed ID: 34625409)
21. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
22. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
Pantaleo A; Forte G; Fasano C; Lepore Signorile M; Sanese P; De Marco K; Di Nicola E; Latrofa M; Grossi V; Disciglio V; Simone C
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201484
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
Chaffee KG; Oberg AL; McWilliams RR; Majithia N; Allen BA; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Petersen GM
Genet Med; 2018 Jan; 20(1):119-127. PubMed ID: 28726808
[TBL] [Abstract][Full Text] [Related]
24. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
[TBL] [Abstract][Full Text] [Related]
25. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
[TBL] [Abstract][Full Text] [Related]
26. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
[TBL] [Abstract][Full Text] [Related]
27. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China.
Yin L; Wei J; Lu Z; Huang S; Gao H; Chen J; Guo F; Tu M; Xiao B; Xi C; Zhang K; Li Q; Wu J; Gao W; Jiang K; Yu J; Miao Y
JAMA Netw Open; 2022 Feb; 5(2):e2148721. PubMed ID: 35171259
[TBL] [Abstract][Full Text] [Related]
29. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Bannon SA; Montiel MF; Goldstein JB; Dong W; Mork ME; Borras E; Hasanov M; Varadhachary GR; Maitra A; Katz MH; Feng L; Futreal A; Fogelman DR; Vilar E; McAllister F
Cancer Prev Res (Phila); 2018 Nov; 11(11):679-686. PubMed ID: 30274973
[No Abstract] [Full Text] [Related]
30. Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers.
Ando Y; Dbouk M; Yoshida T; Abou Diwan E; Saba H; Dbouk A; Yoshida K; Roberts NJ; Klein AP; Burkhart R; He J; Hruban RH; Goggins M
JCO Precis Oncol; 2024 May; 8():e2400101. PubMed ID: 38781545
[TBL] [Abstract][Full Text] [Related]
31. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
32. Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes.
Mizukami K; Iwasaki Y; Kawakami E; Hirata M; Kamatani Y; Matsuda K; Endo M; Sugano K; Yoshida T; Murakami Y; Nakagawa H; Spurdle AB; Momozawa Y
EBioMedicine; 2020 Oct; 60():103033. PubMed ID: 32980694
[TBL] [Abstract][Full Text] [Related]
33. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
[TBL] [Abstract][Full Text] [Related]
34. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract][Full Text] [Related]
35. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
36. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.
Obazee O; Archibugi L; Andriulli A; Soucek P; Małecka-Panas E; Ivanauskas A; Johnson T; Gazouli M; Pausch T; Lawlor RT; Cavestro GM; Milanetto AC; Di Leo M; Pasquali C; Hegyi P; Szentesi A; Radu CE; Gheorghe C; Theodoropoulos GE; Bergmann F; Brenner H; Vodickova L; Katzke V; Campa D; Strobel O; Kaiser J; Pezzilli R; Federici F; Mohelnikova-Duchonova B; Boggi U; Lemstrova R; Johansen JS; Bojesen SE; Chen I; Jensen BV; Capurso G; Pazienza V; Dervenis C; Sperti C; Mambrini A; Hackert T; Kaaks R; Basso D; Talar-Wojnarowska R; Maiello E; Izbicki JR; Cuk K; Saum KU; Cantore M; Kupcinskas J; Palmieri O; Delle Fave G; Landi S; Salvia R; Fogar P; Vashist YK; Scarpa A; Vodicka P; Tjaden C; Iskierka-Jazdzewska E; Canzian F
Int J Cancer; 2019 Aug; 145(3):686-693. PubMed ID: 30672594
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
[TBL] [Abstract][Full Text] [Related]
38. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
39. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
